Browse By: Country ι Category ι Publisher ι Tag

Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors

Pages » 301
Published By » La Merie Publishing
Price » $2092
In stock
View Report Details
Description

Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets: Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) G-CSF & GM-CSF Thrombopoietin & Thrombopoiesis Stimulating Agents Interferon Insulin Coagulation Factors Human Growth Hormone (hGH) FSH, hCG and LH: Therapeutic Pro... Click here for more details


Oncology Pipeline Database: 6-Month Subscription
Oncology Pipeline Database: 6-Month Subscription Product description Subscription to La Merie’s proprietary Oncology Pipeline Database provides online access to more than 3,000 project entries in oncology. Each project is specified for its Target or Mechanism of Action, Product Category and
Published Date: Feb 2010
Price: $1544
Oncology Pipeline Database: 1-Year Subscription
Oncology Pipeline Database: 1-Year Subscription Product description Subscription to La Merie’s proprietary Oncology Pipeline Database provides online access to more than 3,000 project entries in oncology. Each project is specified for its Target or Mechanism of Action, Product Category and R
Published Date: May 2010
Price: $2316
Flat-Rate Subscription to La Merie Reports with 24/7 Online Access
Subscription to this product provides online access during one year to all reports published by La Merie and available in the online store during the subscription. Among La Merie reports are more than 100 Competitor Analysis reports as well as a growing number of Brief and Full Reports. La Merie r
Published Date: Jun 2010
Price: $5146
R&D Drug Pipeline Database: 1-Year Subscription
R&D Drug Pipeline Database: 1-Year Subscription Product description Subscription to La Meries proprietary R&D Drug Pipeline Database provides online access to more than 12,000 project entries in all therapeutic areas and product categories. Each project is specified for its Target or Mecha
Published Date: Aug 2010
Price: $7719
R&D Drug Pipeline Database: 2-Months Subscription
R&D Drug Pipeline Database: 2-Months Subscription Product description Subscription to La Meries proprietary R&D Drug Pipeline Database provides online access to more than 12,000 project entries in all therapeutic areas and product categories. Each project is specified for its Target or Mec
Published Date: Aug 2010
Price: $2573
Antibody Pipeline Database: 1-Year Subscription
Subscription to La Meries proprietary Antibody Pipeline Database provides online access to more than 1,600 project entries for therapeutic antibodies on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase.
Published Date: Nov 2010
Price: $1544
Therapeutic Protein Pipeline Database: 1-Year Subscription
Subscription to La Merie’s proprietary Therapeutic Protein Pipeline Database provides online access to more than 1,700 project entries for therapeutic proteins on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area a
Published Date: Feb 2011
Price: $1544
RNA Therapeutics Pipeline Database: 1-Year Subscription
RNA Therapeutics Pipeline Database: 1-Year Subscription Product description Subscription to La Merie’s proprietary RNA Therapeutics Pipeline Database provides online access to RNA Therapeutics on the market and in research & development. RNA Therapeutics include the classes of antisense,
Published Date: Mar 2011
Price: $772
Vaccine Pipeline Database: 1-Year Subscription
Vaccine Pipeline Database: 1-Year Subscription Product description Subscription to La Merie’s proprietary Vaccine Pipeline Database provides online access to more than 1,200 project entries for prophylactic and therapeutic vaccines on the market and in research & development. Eac
Published Date: Oct 2011
Price: $1287
Competitor Analysis: Targeted Therapy of Hepatitis C
The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online access to
Published Date: Aug 2011
Price: $772

 


 

Related News

China’s Huawei to Setup 4G Network in Cambodia
EMAXX, the Cambodian telecommunications company has signed a deal with the Chinese Huawei on Wednesday to build and develop a 4G network in Cambodia. The contract was signed by Ai Minn, the CEO of EMAXX, and the DGM of Huawei Technologies Weng Kefeng. The signing was performed in the presence of the Chinese Embassy’s Cambodian political councilor Li Zhigong and Kan Channmeta, Secretary of State at the Cambodian Ministry of Posts and Telecom. The contract states that Huawei will build
Date: Sep 18

Cost Watchdog of Britain’s Healthcare Sector Approves GSK’s Melanoma Drug under Price-Cut Conditions
Cost control agency of Britain’s healthcare sector, The National Institute for Health and Care Excellence (NICE), has recommended a drug for melanoma marketed by GlaxoSmithKline after the drug maker offered to supply it at a discounted rate to the National Health Service.  The drug, titled Tafinlar, is currently marketed by GSK but it will soon be transferred to Novartis under a trade deal between the tow companies.  Tafinlar is an oral drug that works in a way similar to R
Date: Sep 18

GFT Publishes Big Data for Financial Services Industry
According to the electronic newsletter issued by the California Independent Petroleum Association on Monday, the refinery project poses major economic questions regarding bringing extra crude barrels into the California market. This will affect the local crude prices in the state.  The oil-by-rail project of Alon USA Energy Inc. on Rosedale Highway stirs several questions regarding the local crude prices in the oil industry of California.  Alon is a Dallas-based oil company that
Date: Sep 18

Weakening Rouble Makes GM Cut Production and Cut Jobs in Russia
Opel Group, the European subsidiary of general Motors has planned to cut production and shed nearly 500 jobs in Russia. The decision comes ahead of the weakening Russian rouble and the drop in local demand due to slow economic growth and Western sanctions. Opel stated that it would cut production from two shifts per day to one, at its St. Petersburg plant where it produces Chevrolet Cruze compact and Opel Astra. The company will also offer voluntary severance letters to nearly 500 of the p
Date: Sep 17

Only 44% Americans Think College Education “Very Important”: Poll
A recent annual poll has revealed some shocking statistics regarding Americans’ views on the need for a college education. The poll showed that only 44% of Americans believed that a college education was “very important”, a drastic drop from 75% just four years ago. The 46th annual PDK-Gallup poll also found that most parents of kids in public schools wish that teacher training programs be more selective and that new teachers work under a certified teacher for at least a yea
Date: Sep 17

Fashion Industry Embraces Technology at London Fashion Week
The London Fashion Week cast the spotlight this week not just on the clothes on the runway, but the technology that surrounded the event. In what could be termed as a new digital first for the fashion industry, Burberry teamed up with Twitter to launch the new click-to-buy button to people across the globe. The British luxury fashion house made its nail paint that will be showcased at the LFW available to Twitterati. The social media website is currently trying out the “buy now” feat
Date: Sep 16

Bitcoin Mining Firm Free from Cease Trade
A Saskatchewan based Dominion Bitcoin Mining Company is now free from cease trade and is operating once again.  The cease-trade order against Bitcoin was lifted in May by the Financial and Consumer Affairs Authority (FCAA) with no penalty being issued after it expired last week.  FCAA’s action toward originally issuing the order was because it believed the mining firm had been looking out for various investors in the Saskatchewan region without actually being registered to
Date: Sep 16

Hawaii Earns a “C” in the Blue Planet Foundation’s 2014 Energy Report Card
According to a report published by Blue Planet Foundation, Hawaii received an “average” grade for its clean energy progress. The Blue Planet Foundation’s 2014 Energy Report Card for Hawaii has shown a slight improvement since 2013 which was at “C-minus”. This year the report card has improved to “C”. The report is a 42-page document which gives a broad perspective of Hawaii’s energy transformation. It overlooks key aspects such as transportation
Date: Sep 16

Coke’s Surge to be Reintroduced in the Global Beverages Market
A flavored drink that was discontinued more than a decade ago by Coca Cola, has again been brought back in the beverages market. This citrus flavored drink called Surge is a Mountain Dew knockoff. This drink is only available at Amazon.com. This happens to be Coca Cola’s first ever e-commerce reintroduction. The reintroduction of Surge has been announced at the “Surge Movement” which is a Facebook Fan site.  The members of this fan site are excited about the return of t
Date: Sep 16

Cipla Rises by 10% in Two Days
In a relatively weaker market, Cipla has managed to rally stocks by 3% up to $10.34, a record high for the pharmaceutical company in the National Stock Exchange (NSE). The latest rally brings the stock for Cipla up by nearly 10% within a span of two days. The stocks rose from a previous $9.46 two days ago. The growth added some relief to a CNX Nifty market that was declining by 1%. The stocks started gaining ground after Cipla launched their anti-asthma inhalers in Germany and Sweden. The
Date: Sep 15

Upcoming Reports

Biopharmaceutical Licensing Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts, 2012 - 2018
The biopharmaceutical industry is focusing on the growing complexity of licensing deals in order to secure marketing and commercialization rights within partnership deals. The major challenge faced by the biopharmaceutical licensing market is asymmetry between licensor and licensees. The biopharma
Published By: Transparency Market Research
Price: $4795
US Biopharmaceutical Market - Global Industry Size, Market Share, Smart Trends, Analysis And Forecast, 2012 - 2018
Biopharmaceuticals are medical drugs which are produced with the help of biotechnology. The US is the largest market for biopharmaceuticals and is the leader in terms of revenue, by a substantial margin. The biopharmaceutical market can be classified based on the class of the medical drug into r
Published By: Transparency Market Research
Price: $4795
Orthopedic Bone Material (Cement and Casting) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
Artificial joints have been anchored with bone cements for more than half a century. Bone cement plays the important role of an elastic zone by filling the space between the prosthesis and the bone. The necessity of bone cement is supported by the fact that the human hip is acted on by 10-12 tim
Published By: Transparency Market Research
Price: $4595
Single-Use Technologies For Biopharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
Single use technologies involve single-use or disposable products. Such products are usually made of plastics or its derivatives such as polyamides, polycarbonates, polyethylene, polyvinyl chloride and various others. These products are becoming popular in the biopharmaceutical applications as the
Published By: Transparency Market Research
Price: $4795